As of 2025-05-23, the EV/EBITDA ratio of Enanta Pharmaceuticals Inc (ENTA) is -0.64. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ENTA's latest enterprise value is 63.78 mil USD. ENTA's TTM EBITDA according to its financial statements is -99.53 mil USD. Dividing these 2 quantities gives us the above ENTA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.2x - 13.3x | 11.5x |
| Forward P/E multiples | 15.5x - 25.0x | 18.0x |
| Fair Price | (69.38) - (59.39) | (66.18) |
| Upside | -1306.6% - -1132.9% | -1251.0% |
| Date | EV/EBITDA |
| 2025-05-22 | -0.64 |
| 2025-05-21 | -0.65 |
| 2025-05-20 | -0.71 |
| 2025-05-19 | -0.69 |
| 2025-05-16 | -0.64 |
| 2025-05-15 | -0.56 |
| 2025-05-14 | -0.52 |
| 2025-05-13 | -0.53 |
| 2025-05-12 | -0.60 |
| 2025-05-09 | -0.54 |
| 2025-05-08 | -0.55 |
| 2025-05-07 | -0.49 |
| 2025-05-06 | -0.49 |
| 2025-05-05 | -0.57 |
| 2025-05-02 | -0.68 |
| 2025-05-01 | -0.71 |
| 2025-04-30 | -0.71 |
| 2025-04-29 | -0.65 |
| 2025-04-28 | -0.62 |
| 2025-04-25 | -0.60 |
| 2025-04-24 | -0.62 |
| 2025-04-23 | -0.61 |
| 2025-04-22 | -0.59 |
| 2025-04-21 | -0.53 |
| 2025-04-17 | -0.50 |
| 2025-04-16 | -0.47 |
| 2025-04-15 | -0.51 |
| 2025-04-14 | -0.47 |
| 2025-04-11 | -0.41 |
| 2025-04-10 | -0.32 |
| 2025-04-09 | -0.37 |
| 2025-04-08 | -0.36 |
| 2025-04-07 | -0.40 |
| 2025-04-04 | -0.42 |
| 2025-04-03 | -0.49 |
| 2025-04-02 | -0.54 |
| 2025-04-01 | -0.55 |
| 2025-03-31 | -0.59 |
| 2025-03-28 | -0.63 |
| 2025-03-27 | -0.66 |
| 2025-03-26 | -0.66 |
| 2025-03-25 | -0.67 |
| 2025-03-24 | -0.74 |
| 2025-03-21 | -0.76 |
| 2025-03-20 | -0.79 |
| 2025-03-19 | -0.79 |
| 2025-03-18 | -0.76 |
| 2025-03-17 | -0.72 |
| 2025-03-14 | -0.83 |
| 2025-03-13 | -0.87 |